Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 287640, 16 pages
http://dx.doi.org/10.1155/2015/287640
Review Article

Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy

1Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al-’Abdiyah Campus, P. O. Box 7607, Makkah, Saudi Arabia
2Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut 6515, Egypt
3Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia
4Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia

Received 10 January 2015; Revised 27 February 2015; Accepted 27 February 2015

Academic Editor: Limin Chen

Copyright © 2015 Bassem Refaat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Refaat, A. M. Ashshi, A. G. El-Shemi, and A. AlZanbagi, “Effects of chronic hepatitis C genotype 1 and 4 on serum activins and follistatin in treatment naive patients and their correlations with interleukin-6, tumour necrosis factor-α, viral load and liver damage,” Clinical and Experimental Medicine, 2014. View at Publisher · View at Google Scholar
  2. B. Refaat, A. G. El-Shemi, A. M. Ashshi, and A. Alzanbagi, “Serum activins and follistatin during the treatment of chronic hepatitis c genotypes 1 and 4 and their correlations with viral load and liver enzymes: a preliminary report,” Gastroenterology Research and Practice, vol. 2014, Article ID 628683, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. T. A. Madani, “Hepatitis C virus infections reported in Saudi Arabia over 11 years of surveillance,” Annals of Saudi Medicine, vol. 27, no. 3, pp. 191–194, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. T. A. Madani, “Hepatitis C virus infections reported over 11 years of surveillance in Saudi Arabia,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 103, no. 2, pp. 132–136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. S. Lee and P. Ferenci, “Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4,” Antiviral Therapy, vol. 13, supplement 1, pp. 9–16, 2008. View at Google Scholar · View at Scopus
  7. A. Tsubota, K. Fujise, Y. Namiki, and N. Tada, “Peginterferon and ribavirin treatment for hepatitis C virus infection,” World Journal of Gastroenterology, vol. 17, no. 4, pp. 419–432, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Metts, L. Carmichael, W. Kokor, and R. Scharffenberg, “Hepatitis C: existing and new treatments,” FP Essentials, vol. 427, pp. 18–24, 2014. View at Google Scholar
  9. C. M. Lange and S. Zeuzem, “Perspectives and challenges of interferon-free therapy for chronic hepatitis C,” Journal of Hepatology, vol. 58, no. 3, pp. 583–592, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. Z. M. Younossi, M. E. Singer, H. M. Mir, L. Henry, and S. Hunt, “Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients,” Journal of Hepatology, vol. 60, no. 3, pp. 530–537, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Chan, M. N. Lai, E. J. Groessl et al., “Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic hcv genotype 1 infection in the veterans health administration,” Clinical Gastroenterology and Hepatology, vol. 11, no. 11, pp. 1503–1510, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. A. Ferrante, J. Chhatwal, C. A. Brass et al., “Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study,” BMC Infectious Diseases, vol. 13, no. 1, article 190, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Cure, F. Bianic, S. Gavart, S. Curtis, S. Lee, and G. Dusheiko, “Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients,” Journal of Medical Economics, vol. 17, no. 1, pp. 65–76, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. G. M. Lauer and B. D. Walker, “Hepatitis C virus infection,” The New England Journal of Medicine, vol. 345, no. 1, pp. 41–52, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Fallahi, C. Ferri, S. M. Ferrari, A. Corrado, D. Sansonno, and A. Antonelli, “Cytokines and HCV-related disorders,” Clinical and Developmental Immunology, vol. 2012, Article ID 468107, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. R. E. Lanford, B. Guerra, D. Chavez et al., “Cross-genotype immunity to hepatitis C virus,” Journal of Virology, vol. 78, no. 3, pp. 1575–1581, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. M. H. Heim and R. Thimme, “Innate and adaptive immune responses in HCV infections,” Journal of Hepatology, vol. 61, no. 1, pp. S14–S25, 2014. View at Publisher · View at Google Scholar
  18. M.-T. Wong and S. S.-L. Chen, “Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection,” Cellular & Molecular Immunology, 2014. View at Publisher · View at Google Scholar
  19. M. A. Ibrahim, A. A. Mostafa, H. W. El-Said, A. M. Mohab, and H. A. Hebah, “Study of peripheral blood natural killer cells, T-cell helper/T-cell suppressor ratio and intercurrent infection frequency in hepatitis C seropositive prevalent hemodialysis patients,” Hemodialysis International, vol. 18, supplement 1, pp. S23–S31, 2014. View at Publisher · View at Google Scholar
  20. M. T. Dill, Z. Makowska, F. H. T. Duong et al., “Interferon-γstimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C,” Gastroenterology, vol. 143, no. 3, pp. 777.e1-6–786.e1-6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Jinushi, T. Takehara, T. Kanto et al., “Critical role of MHC class I-related chain A and B expression on IFN-α-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection,” Journal of Immunology, vol. 170, no. 3, pp. 1249–1256, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Barth, R. Klein, P. A. Berg, B. Wiedenmann, U. Hopf, and T. Berg, “Analysis of the effect of IL-12 therapy on immunoregulatory T-cell subsets in patients with chronic hepatitis C infection,” Hepato-Gastroenterology, vol. 50, no. 49, pp. 201–206, 2003. View at Google Scholar · View at Scopus
  23. Z. Makowska, F. H. T. Duong, G. Trincucci, D. F. Tough, and M. H. Heim, “Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-αin vivo,” Hepatology, vol. 53, no. 4, pp. 1154–1163, 2011. View at Google Scholar · View at Scopus
  24. E. Thomas, V. D. Gonzalez, Q. Li et al., “HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons,” Gastroenterology, vol. 142, no. 4, pp. 978–988, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Golden-Mason, Y. S. Hahn, M. Strong, L. Cheng, and H. R. Rosen, “Extracellular HCV-core protein induces an immature regulatory phenotype in NK cells: implications for outcome of acute infection,” PLoS ONE, vol. 9, no. 7, Article ID e103219, 2014. View at Publisher · View at Google Scholar
  26. C.-T. K. Tseng and G. R. Klimpel, “Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions,” Journal of Experimental Medicine, vol. 195, no. 1, pp. 43–49, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Weber and R. Thimme, “Viral anti-interferon strategies: mechanisms and clinical impact,” Deutsche Medizinische Wochenschrift, vol. 128, no. 7, pp. 323–325, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Murata, M. Sugiyama, T. Kimura et al., “Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients,” Journal of Gastroenterology, vol. 49, no. 1, pp. 126–137, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Pelletier, N. Bédard, E. Said, P. Ancuta, J. Bruneau, and N. H. Shoukry, “Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C,” Journal of Virology, vol. 87, no. 12, pp. 6769–6781, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. B.-S. Liu, H. L. A. Janssen, and A. Boonstra, “Type I and III interferons enhance IL-10R expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12,” European Journal of Immunology, vol. 42, no. 9, pp. 2431–2440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. B. S. Liu, Z. M. A. Groothuismink, H. L. A. Janssen, and A. Boonstra, “Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections,” Journal of Leukocyte Biology, vol. 89, no. 6, pp. 981–988, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Pelletier, C. Drouin, N. Bédard, S. I. Khakoo, J. Bruneau, and N. H. Shoukry, “Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses,” Journal of Hepatology, vol. 53, no. 5, pp. 805–816, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. I. F. Charo and R. M. Ransohoff, “Mechanisms of disease: the many roles of chemokines and chemokine receptors in inflammation,” The New England Journal of Medicine, vol. 354, no. 6, pp. 610–621, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Ouaguia, D. Mrizak, S. Renaud, O. Moralès, and N. Delhem, “Control of the inflammatory response mechanisms mediated by natural and induced regulatory T-cells in HCV-, HTLV-1-, and EBV-associated cancers,” Mediators of Inflammation, vol. 2014, Article ID 564296, 15 pages, 2014. View at Publisher · View at Google Scholar
  35. J. Li, K. Men, Y. Yang, and D. Li, “Dynamical analysis on a chronic hepatitis C virus infection model with immune response,” Journal of Theoretical Biology, vol. 365, pp. 337–346, 2015. View at Publisher · View at Google Scholar · View at MathSciNet
  36. J. R. Larrubia, S. Benito-Martínez, M. Calvino, E. Sanz-de-Villalobos, and T. Parra-Cid, “Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection,” World Journal of Gastroenterology, vol. 14, no. 47, pp. 7149–7159, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Zhang, C. Q. Hao, L. Miao, and X. G. Dou, “Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy,” Genetics and Molecular Research, vol. 13, no. 4, pp. 9747–9755, 2014. View at Publisher · View at Google Scholar
  38. T. Shirasaki, M. Honda, T. Shimakami et al., “Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway,” Hepatology, vol. 60, no. 5, pp. 1519–1530, 2014. View at Publisher · View at Google Scholar
  39. W. M. Gomaa, M. A. Ibrahim, and M. E. Shatat, “Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients,” Saudi Journal of Gastroenterology, vol. 20, no. 1, pp. 59–65, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. S. R. Nallagatla, R. Toroney, and P. C. Bevilacqua, “Regulation of innate immunity through RNA structure and the protein kinase PKR,” Current Opinion in Structural Biology, vol. 21, no. 1, pp. 119–127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. C. X. George, Z. Gan, Y. Liu, and C. E. Samuel, “Adenosine deaminases acting on RNA, RNA editing, and interferon action,” Journal of Interferon and Cytokine Research, vol. 31, no. 1, pp. 99–117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. T. T. Tran, “A review of standard and newer treatment strategies in hepatitis C,” The American Journal of Managed Care, vol. 18, no. 14, pp. S340–S349, 2012. View at Google Scholar · View at Scopus
  43. N. H. Afdhal, S. Zeuzem, R. T. Schooley et al., “The new paradigm of hepatitis C therapy: integration of oral therapies into best practices,” Journal of Viral Hepatitis, vol. 20, no. 11, pp. 745–760, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Alexopoulou and G. V. Papatheodoridis, “Current progress in the treatment of chronic hepatitis C,” World Journal of Gastroenterology, vol. 18, no. 42, pp. 6060–6069, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Abenavoli, M. Mazza, and P. L. Almasio, “The optimal dose of ribavirin for chronic hepatitis C: from literature evidence to clinical practice: the optimal dose of ribavirin for chronic hepatitis C,” Hepatitis Monthly, vol. 11, no. 4, pp. 240–246, 2011. View at Google Scholar · View at Scopus
  46. EASL, “EASL recommendations on treatment of hepatitis C 2014,” Journal of Hepatology, vol. 61, no. 2, pp. 373–395, 2014. View at Publisher · View at Google Scholar
  47. N. K. Gatselis, K. Zachou, A. Saitis, M. Samara, and G. N. Dalekos, “Individualization of chronic hepatitis C treatment according to the host characteristics,” World Journal of Gastroenterology, vol. 20, no. 11, pp. 2839–2853, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. J. T. Blackard, L. Kong, A. K. Huber, and Y. Tomer, “Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis,” Thyroid, vol. 23, no. 7, pp. 863–870, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Menconi, A. Hasham, and Y. Tomer, “Environmental triggers of thyroiditis: hepatitis C and interferon-alpha,” Journal of Endocrinological Investigation, vol. 34, no. 1, pp. 78–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Tomer, “Hepatitis C and interferon induced thyroiditis,” Journal of Autoimmunity, vol. 34, no. 3, pp. J322–J326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. T. L. Oliveira, A. Z. Caetano, J. M. Belem, B. C. Klemz, and M. M. Pinheiro, “Interferon-alpha induced psoriatic arthritis and autoimmune hemolytic anemia during chronic hepatitis C treatment,” Acta Reumatológica Portuguesa, vol. 39, no. 4, pp. 327–330, 2014. View at Google Scholar
  52. R. Ennaifer, M. Cheikh, H. Romdhane, R. Hefaiedh, H. B. Nejma, and N. B. Hadj, “Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin,” Tunisie Medicale, vol. 92, no. 1, pp. 42–43, 2014. View at Google Scholar · View at Scopus
  53. Y. Dahlan, H.-M. Ather, M. Al-ahmadi, F. Batwa, and W. Al-hamoudi, “Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population,” World Journal of Gastroenterology, vol. 15, no. 35, pp. 4429–4433, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Arnaud, C. Trepo, and M. A. Petit, “Predictors of the therapeutic response in hepatitis C. A 2013 update,” Clinics and Research in Hepatology and Gastroenterology, vol. 38, no. 1, pp. 12–17, 2014. View at Publisher · View at Google Scholar
  55. L. Berry and W. Irving, “Predictors of hepatitis C treatment response: what's new?” Expert Review of Anti-Infective Therapy, vol. 12, no. 2, pp. 183–191, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. Kondo, K. Machida, H. M. Liu et al., “Hepatitis C virus infection of T cells inhibits proliferation and enhances Fas-mediated apoptosis by down-regulating the expression of CD44 splicing variant 6,” Journal of Infectious Diseases, vol. 199, no. 5, pp. 726–736, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. M. H. Heim, “Interferons and hepatitis C virus,” Swiss Medical Weekly, vol. 142, Article ID w13586, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Ahlenstiel, B. Edlich, L. J. Hogdal et al., “Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C,” Gastroenterology, vol. 141, no. 4, pp. 1231–1239, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. E.-J. Pavón-Castillero, P. Muñoz-de-Rueda, R. López-Segura et al., “Importance of IL-10 and IL-6 during chronic hepatitis c genotype-1 treatment and their relation with IL28B,” Cytokine, vol. 61, no. 2, pp. 595–601, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. K. S. O'Connor, J. George, D. Booth, and G. Ahlenstiel, “Dendritic cells in hepatitis C virus infection: key players in the -genotype response,” World Journal of Gastroenterology, vol. 20, pp. 17830–17838, 2014. View at Google Scholar
  61. M. A. Jimenez-Sousa, R. Almansa, C. de La Fuente et al., “Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin,” European Cytokine Network, vol. 21, no. 2, pp. 84–91, 2010. View at Google Scholar · View at Scopus
  62. M. Ueyama, M. Nakagawa, N. Sakamoto et al., “Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-alpha2b plus ribavirin,” Antiviral Therapy, vol. 16, no. 7, pp. 1081–1091, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Krause, G. Valesini, R. Scrivo, and Y. Shoenfeld, “Autoimmune aspects of cytokine and anticytokine therapies,” The American Journal of Medicine, vol. 115, no. 5, pp. 390–397, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Birerdinc, A. Afendy, M. Stepanova et al., “Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C,” Journal of Viral Hepatitis, vol. 17, no. 10, pp. 730–736, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Laouar, F. S. Sutterwala, L. Gorelik, and R. A. Flavell, “Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ,” Nature Immunology, vol. 6, no. 6, pp. 600–607, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Ling, S.-Y. Ying, N. Ueno, S. Shimasaki, F. E. M. Hotta, and R. Guillemin, “A homodimer of the β-subunits of inhibin a stimulates the secretion of pituitary follicle stimulating hormone,” Biochemical and Biophysical Research Communications, vol. 138, no. 3, pp. 1129–1137, 1986. View at Publisher · View at Google Scholar · View at Scopus
  67. N. Ling, S.-Y. Ying, N. Ueno et al., “Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin,” Nature, vol. 321, no. 6072, pp. 779–782, 1986. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Yasuda, T. Mine, H. Shibata et al., “Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes,” The Journal of Clinical Investigation, vol. 92, no. 3, pp. 1491–1496, 1993. View at Publisher · View at Google Scholar · View at Scopus
  69. H. Ooe, Q. Chen, J. Kon et al., “Proliferation of rat small hepatocytes requires follistatin expression,” Journal of Cellular Physiology, vol. 227, no. 6, pp. 2363–2370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Menthena, C. I. Koehler, J. S. Sandhu et al., “Activin A, p15INK4b signaling, and cell competition promote stem/progenitor cell repopulation of livers in aging rats,” Gastroenterology, vol. 140, no. 3, pp. 1009–1020, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. O. A. Gressner, B. Lahme, M. Siluschek, K. Rehbein, R. Weiskirchen, and A. M. Gressner, “Intracrine signalling of activin A in hepatocytes upregulates connective tissue growth factor (CTGF/CCN2) expression,” Liver International, vol. 28, no. 9, pp. 1207–1216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Sideras, E. Apostolou, A. Stavropoulos et al., “Activin, neutrophils, and inflammation: just coincidence?” Seminars in Immunopathology, vol. 35, no. 4, pp. 481–499, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. E. Petrakou, S. Fotopoulos, M. Anagnostakou et al., “Activin-A exerts a crucial anti-inflammatory role in neonatal infections,” Pediatric Research, vol. 74, no. 6, pp. 675–681, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. W. Vale, J. Rivier, J. Vaughan et al., “Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid,” Nature, vol. 321, no. 6072, pp. 776–779, 1986. View at Publisher · View at Google Scholar · View at Scopus
  75. D. E. Barton, T. L. Yang-Feng, A. J. Mason, P. H. Seeburg, and U. Francke, “Mapping of genes for inhibin subunits alpha, beta A, and beta B on human and mouse chromosomes and studies of jsd mice,” Genomics, vol. 5, no. 1, pp. 91–99, 1989. View at Publisher · View at Google Scholar · View at Scopus
  76. A. J. Mason, J. S. Hayflick, N. Ling et al., “Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-β,” Nature, vol. 318, no. 6047, pp. 659–663, 1985. View at Publisher · View at Google Scholar · View at Scopus
  77. B. A. Refaat, A. O. Bahathiq, S. Sockanathan, R. L. Stewart, M. Wells, and W. L. Ledger, “Production and localization of activins and activin type IIA and IIB receptors by the human endosalpinx,” Reproduction, vol. 128, no. 2, pp. 249–255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Ebner, R.-H. Chen, S. Lawler, T. Zioncheck, and R. Derynck, “Determination of type I receptor specificity by the type II receptors for TGF-β or activin,” Science, vol. 262, no. 5135, pp. 900–902, 1993. View at Publisher · View at Google Scholar · View at Scopus
  79. J. L. Wrana, H. Tran, L. Attisano et al., “Two distinct transmembrane serine/threonine kinases from Drosophila melanogaster form an activin receptor complex,” Molecular and Cellular Biology, vol. 14, no. 2, pp. 944–950, 1994. View at Google Scholar · View at Scopus
  80. A. L. Schneyer, H. A. Hall, G. Lambert-messerlian, Q. F. Wang, P. Sluss, and W. F. Crowley Jr., “Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically,” Endocrinology, vol. 137, no. 1, pp. 240–247, 1996. View at Google Scholar · View at Scopus
  81. T. B. Thompson, T. F. Lerch, R. W. Cook, T. K. Woodruff, and T. S. Jardetzky, “The structure of the follistatin: activin complex reveals antagonism of both type I and type II receptor binding,” Developmental Cell, vol. 9, no. 4, pp. 535–543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Rodgarkia-Dara, S. Vejda, N. Erlach et al., “The activin axis in liver biology and disease,” Mutation Research, vol. 613, no. 2-3, pp. 123–137, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. D.-H. Wang, Y.-N. Wang, J.-Y. Ge et al., “Role of activin A in carbon tetrachloride-induced acute liver injury,” World Journal of Gastroenterology, vol. 19, no. 24, pp. 3802–3809, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Ebert, M. Zeretzke, R. Nau, and U. Michel, “Microglial cells and peritoneal macrophages release activin A upon stimulation with Toll-like receptor agonists,” Neuroscience Letters, vol. 413, no. 3, pp. 241–244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. D. J. Phillips, D. M. de Kretser, and M. P. Hedger, “Activin and related proteins in inflammation: not just interested bystanders,” Cytokine and Growth Factor Reviews, vol. 20, no. 2, pp. 153–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. N. C. Robson, D. J. Phillips, T. McAlpine et al., “Activin-A: a novel dendritic cell derived cytokine that potently attenuates CD40 ligand specific cytokine and chemokine production,” Blood, vol. 111, no. 5, pp. 2733–2743, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. P. Seeger, D. Bosisio, S. Parolini et al., “Activin A as a mediator of NK-dendritic cell functional interactions,” The Journal of Immunology, vol. 192, no. 3, pp. 1241–1248, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. K. Ogawa, M. Funaba, Y. Chen, and M. Tsujimoto, “Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages,” Journal of Immunology, vol. 177, no. 10, pp. 6787–6794, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Ogawa, M. Funaba, and M. Tsujimoto, “A dual role of activin A in regulating immunoglobulin production of B cells,” Journal of Leukocyte Biology, vol. 83, no. 6, pp. 1451–1458, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. K. L. Jones, A. Mansell, S. Patella et al., “Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 41, pp. 16239–16244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. K. Ogawa and M. Funaba, “Activin in humoral immune responses,” Vitamins and Hormones, vol. 85, pp. 235–253, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. K. L. Jones, D. M. de Kretser, I. J. Clarke, J.-P. Y. Scheerlinck, and D. J. Phillips, “Characterisation of the rapid release of activin A following acute lipopolysaccharide challenge in the ewe,” Journal of Endocrinology, vol. 182, no. 1, pp. 69–80, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. H. Wu, Y. Chen, W. R. Winnall, D. J. Phillips, and M. P. Hedger, “Acute regulation of activin A and its binding protein, follistatin, in serum and tissues following lipopolysaccharide treatment of adult male mice,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 303, no. 6, pp. R665–R675, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Werner and C. Alzheimer, “Roles of activin in tissue repair, fibrosis, and inflammatory disease,” Cytokine and Growth Factor Reviews, vol. 17, no. 3, pp. 157–171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. M. P. Hedger and D. M. de Kretser, “The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis,” Cytokine and Growth Factor Reviews, vol. 24, no. 3, pp. 285–295, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. F. Dong and X. He, “Activin A: a potential therapeutic target for characterizing and stopping joint pain early in rheumatoid arthritis patients,” Inflammation, vol. 37, no. 1, pp. 170–176, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. C.-H. Chen, J. Y.-C. Lin, F.-H. Liu, J.-L. Chang, and H.-M. Huang, “Basic fibroblast growth factor inhibits p38-mediated cell differentiation and growth inhibition by activin A but not by histone deacetylase inhibitors in CML cells,” Annals of Hematology, vol. 87, no. 3, pp. 175–182, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. C. P. Jones, L. G. Gregory, B. Causton, G. A. Campbell, and C. M. Lloyd, “Activin A and TGF-β promote T H9 cell-mediated pulmonary allergic pathology,” Journal of Allergy and Clinical Immunology, vol. 129, no. 4, pp. 1000–1010, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. M. P. Hedger, W. R. Winnall, D. J. Phillips, and D. M. de Kretser, “The regulation and functions of activin and follistatin in inflammation and immunity,” Vitamins & Hormones, vol. 85, pp. 255–297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Semitekolou, T. Alissafi, M. Aggelakopoulou et al., “Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease,” Journal of Experimental Medicine, vol. 206, no. 8, pp. 1769–1785, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. H. H. Kariyawasam, M. Semitekolou, D. S. Robinson, and G. Xanthou, “Activin-A: a novel critical regulator of allergic asthma,” Clinical & Experimental Allergy, vol. 41, no. 11, pp. 1505–1514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. K. S. Famulski, B. Sis, L. Billesberger, and P. F. Halloran, “Interferon-gamma and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: a shift in the Th1-Th2 paradigm,” The American Journal of Transplantation, vol. 8, no. 3, pp. 547–556, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. A. L. Blount, K. Schmidt, N. J. Justice, W. W. Vale, W. H. Fischer, and L. M. Bilezikjian, “FoxL2 and Smad3 coordinately regulate follistatin gene transcription,” The Journal of Biological Chemistry, vol. 284, no. 12, pp. 7631–7645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. A. L. Blount, J. M. Vaughan, W. W. Vale, and L. M. Bilezikjian, “A smad-binding element in intron 1 participates in activin-dependent regulation of the follistatin gene,” Journal of Biological Chemistry, vol. 283, no. 11, pp. 7016–7026, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. K. M. Wilson, A. I. Smith, and D. J. Phillips, “Stimulatory effects of lipopolysaccharide on endothelial cell activin and follistatin,” Molecular and Cellular Endocrinology, vol. 253, no. 1-2, pp. 30–35, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Abe, Y. Shintani, Y. Eto et al., “Interleukin-1 β enhances and interferon-γ suppresses activin A actions by reciprocally regulating activin A and follistatin secretion from bone marrow stromal fibroblasts,” Clinical and Experimental Immunology, vol. 126, no. 1, pp. 64–68, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. J. A. Keelan, R. L. Zhou, L. W. Evans, N. P. Groome, and M. D. Mitchell, “Regulation of activin A, inhibin A, and follistatin production in human amnion and choriodecidual explants by inflammatory mediators,” Journal of the Society for Gynecologic Investigation, vol. 7, no. 5, pp. 291–296, 2000. View at Publisher · View at Google Scholar · View at Scopus
  108. S. Abe, M. Soejima, O. Iwanuma et al., “Expression of myostatin and follistatin in mdx mice, an animal model for muscular dystrophy,” Zoological Science, vol. 26, no. 5, pp. 315–320, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Wankell, S. Kaesler, Y.-Q. Zhang, C. Florence, S. Werner, and R. Duan, “The activin binding proteins follistatin and follistatin-related protein are differentially regulated in vitro and during cutaneous wound repair,” Journal of Endocrinology, vol. 171, no. 3, pp. 385–395, 2001. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Mukhopadhyay, Y. C. Sui, I. J. Lim, D. J. Phillips, and T. T. Phan, “The role of the activin system in keloid pathogenesis,” The American Journal of Physiology—Cell Physiology, vol. 292, no. 4, pp. C1331–C1338, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. D. Endo, K. Kogure, Y. Hasegawa, M. Maku-uchi, and I. Kojima, “Activin A augments vascular endothelial growth factor activity in promoting branching tubulogenesis in hepatic sinusoidal endothelial cells,” Journal of Hepatology, vol. 40, no. 3, pp. 399–404, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. T. Ichikawa, Y.-Q. Zhang, K. Kogure et al., “Transforming growth factor β and activin tonically inhibit DNA synthesis in the rat liver,” Hepatology, vol. 34, no. 5, pp. 918–925, 2001. View at Publisher · View at Google Scholar · View at Scopus
  113. K. Kogure, Y.-Q. Zhang, A. Maeshima, K. Suzuki, H. Kuwano, and I. Kojima, “The role of activin and transforming growth factor-beta in the regulation of organ mass in the rat liver,” Hepatology, vol. 31, no. 4, pp. 916–921, 2000. View at Publisher · View at Google Scholar · View at Scopus
  114. K. Takabe, J. J. Lebrun, Y. Nagashima et al., “Interruption of activin A autocrine regulation by antisense oligodeoxynucleotides accelerates liver tumor cell proliferation,” Endocrinology, vol. 140, no. 7, pp. 3125–3132, 1999. View at Google Scholar · View at Scopus
  115. K. Takabe, L. Wang, A. M. O. Leal et al., “Adenovirus-mediated overexpression of follistatin enlarges intact liver of adult rats,” Hepatology, vol. 38, no. 5, pp. 1107–1115, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. D. J. Phillips, K. L. Jones, I. J. Clarke, J.-P. Y. Scheerlinck, and D. M. De Kretser, “Activin A: from sometime reproductive factor to genuine cytokine,” Veterinary Immunology and Immunopathology, vol. 108, no. 1-2, pp. 23–27, 2005. View at Publisher · View at Google Scholar · View at Scopus
  117. E. J. Gold, X. Zhang, A. M. Wheatley et al., “βA- and βC-activin, follistatin, activin receptor mRNA and βC-activin peptide expression during rat liver regeneration,” Journal of Molecular Endocrinology, vol. 34, no. 2, pp. 505–515, 2005. View at Publisher · View at Google Scholar · View at Scopus
  118. E. J. Gold, R. J. B. Francis, A. Zimmermann et al., “Changes in activin and activin receptor subunit expression in rat liver during the development of CCl4-induced cirrhosis,” Molecular and Cellular Endocrinology, vol. 201, no. 1-2, pp. 143–153, 2003. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Chabicovsky, K. Herkner, and W. Rossmanith, “Overexpression of activin beta(C) or activin beta(E) in the mouse liver inhibits regenerative deoxyribonucleic acid synthesis of hepatic cells,” Endocrinology, vol. 144, no. 8, pp. 3497–3504, 2003. View at Publisher · View at Google Scholar · View at Scopus
  120. F. Verrecchia and A. Mauviel, “Transforming growth factor-β and fibrosis,” World Journal of Gastroenterology, vol. 13, no. 22, pp. 3056–3062, 2007. View at Google Scholar · View at Scopus
  121. S. Tashiro, “Mechanism of liver regeneration after liver resection and portal vein embolization (ligation) is different?” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 16, no. 3, pp. 292–299, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. M. Sugiyama, T. Ichida, T. Sato, T. Ishikawa, Y. Matsuda, and H. Asakura, “Expression of activin A is increased in cirrhotic and fibrotic rat livers,” Gastroenterology, vol. 114, no. 3, pp. 550–558, 1998. View at Publisher · View at Google Scholar · View at Scopus
  123. P. J. de Bleser, T. Niki, G. Xu, V. Rogiers, and A. Geerts, “Localization and cellular sources of activins in normal and fibrotic rat liver,” Hepatology, vol. 26, no. 4, pp. 905–912, 1997. View at Publisher · View at Google Scholar · View at Scopus
  124. X. Huang, D. G. Li, Z. R. Wang et al., “Expression changes of activin A in the development of hepatic fibrosis,” World Journal of Gastroenterology, vol. 7, no. 1, pp. 37–41, 2001. View at Google Scholar · View at Scopus
  125. X. Huang, D. Li, H. Lu et al., “Expression of activins, follistatin mRNA in the development of hepatic fibrosis,” Chinese Journal of Hepatology, vol. 10, no. 2, pp. 85–88, 2002. View at Google Scholar · View at Scopus
  126. M. Grusch, C. Drucker, B. Peter-Vörösmarty et al., “Deregulation of the activin/follistatin system in hepatocarcinogenesis,” Journal of Hepatology, vol. 45, no. 5, pp. 673–680, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. M. Y. Elsammak, G. M. Amin, G. M. Khalil, W. S. Ragab, and M. M. Abaza, “Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis,” Clinical Biochemistry, vol. 39, no. 6, pp. 623–629, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Patella, D. J. Phillips, D. M. de Kretser, L. W. Evans, N. P. Groome, and W. Sievert, “Characterization of serum activin-A and follistatin and their relation to virological and histological determinants in chronic viral hepatitis,” Journal of Hepatology, vol. 34, no. 4, pp. 576–583, 2001. View at Publisher · View at Google Scholar · View at Scopus
  129. A. Voumvouraki, G. Notas, M. Koulentaki, M. Georgiadou, S. Klironomos, and E. Kouroumalis, “Increased serum activin-A differentiates alcoholic from cirrhosis of other aetiologies,” European Journal of Clinical Investigation, vol. 42, no. 8, pp. 815–822, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. S. D. Lin, T. Kawakami, A. Ushio et al., “Ratio of circulating follistatin and activin A reflects the severity of acute liver injury and prognosis in patients with acute liver failure,” Journal of Gastroenterology and Hepatology, vol. 21, no. 2, pp. 374–380, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. R. D. Hughes and L. W. Evans, “Activin A and follistatin in acute liver failure,” European Journal of Gastroenterology and Hepatology, vol. 15, no. 2, pp. 127–131, 2003. View at Publisher · View at Google Scholar · View at Scopus
  132. M.-F. Yuen, S. Norris, L. W. Evans, P. G. Langley, and R. D. Hughes, “Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis,” Scandinavian Journal of Gastroenterology, vol. 37, no. 2, pp. 233–238, 2002. View at Publisher · View at Google Scholar · View at Scopus
  133. M. Pirisi, C. Fabris, S. Luisi et al., “Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma,” Cancer Detection and Prevention, vol. 24, no. 2, pp. 150–155, 2000. View at Google Scholar · View at Scopus
  134. E. Kreidl, D. Ozturk, T. Metzner, W. Berger, and M. Grusch, “Activins and follistatins: emerging roles in liver physiology and cancer,” World Journal of Hepatology, vol. 1, no. 1, pp. 17–27, 2009. View at Publisher · View at Google Scholar
  135. F. M. Averhoff, N. Glass, and D. Holtzman, “Global burden of hepatitis C: considerations for healthcare providers in the United States,” Clinical Infectious Diseases, vol. 55, supplement 1, pp. S10–S15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  136. D. S. Bowden and M. D. Berzsenyi, “Chronic hepatitis C virus infection: genotyping and its clinical role,” Future microbiology, vol. 1, pp. 103–112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. H. I. Al Ashgar, M. Q. Khan, M. Al-Ahdal et al., “Hepatitis C genotype 4: genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia,” Saudi Journal of Gastroenterology, vol. 19, no. 1, pp. 28–33, 2013. View at Publisher · View at Google Scholar · View at Scopus
  138. M. Stamouli, I. Panagiotou, D. Kairis, A. Michopoulou, A. Skliris, and G. Totos, “Genotype distribution in chronic hepatitis C patients in Greece,” Clinical Laboratory, vol. 58, no. 1-2, pp. 173–176, 2012. View at Google Scholar · View at Scopus
  139. S. Karatapanis, P. Tsoplou, V. Papastergiou et al., “Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island,” Journal of Medical Virology, vol. 84, no. 2, pp. 223–228, 2012. View at Publisher · View at Google Scholar · View at Scopus
  140. Y. Nishino, R. Ooishi, S. Kurokawa et al., “Gene expression of the TGF-β family in rat brain infected with Borna disease virus,” Microbes and Infection, vol. 11, no. 8-9, pp. 737–743, 2009. View at Publisher · View at Google Scholar · View at Scopus
  141. P. Carrega and G. Ferlazzo, “Natural killer cell distribution and trafficking in human tissues,” Frontiers in Immunology, vol. 3, article 347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  142. M. A. Degli-Esposti and M. J. Smyth, “Close encounters of different kinds: dendritic cells and NK cells take centre stage,” Nature Reviews Immunology, vol. 5, no. 2, pp. 112–124, 2005. View at Publisher · View at Google Scholar · View at Scopus
  143. M. U. Mondelli, S. Varchetta, and B. Oliviero, “Natural killer cells in viral hepatitis: facts and controversies,” European Journal of Clinical Investigation, vol. 40, no. 9, pp. 851–863, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. J. M. Werner, E. Serti, X. Chepa-Lotrea et al., “Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection,” Hepatology, vol. 60, no. 4, pp. 1160–1169, 2014. View at Publisher · View at Google Scholar
  145. K. A. Holder, R. S. Russell, and M. D. Grant, “Natural killer cell function and dysfunction in hepatitis C virus infection,” BioMed Research International, vol. 2014, Article ID 903764, 9 pages, 2014. View at Publisher · View at Google Scholar
  146. G. Ahlenstiel, R. H. Titerence, C. Koh et al., “Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner,” Gastroenterology, vol. 138, no. 1, pp. 325–335, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. Z. Tian, Y. Chen, and B. Gao, “Natural killer cells in liver disease,” Hepatology, vol. 57, no. 4, pp. 1654–1662, 2013. View at Publisher · View at Google Scholar · View at Scopus
  148. S. Varchetta, D. Mele, S. Mantovani et al., “Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection,” Hepatology, vol. 56, no. 3, pp. 841–849, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. F.-S. Wang and Z. Zhang, “Liver: how can acute-on-chronic liver failure be accurately identified?” Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 7, pp. 390–391, 2013. View at Publisher · View at Google Scholar · View at Scopus
  150. N. C. Robson, H. Wei, T. McAlpine, N. Kirkpatrick, J. Cebon, and E. Maraskovsky, “Activin-A attenuates several human natural killer cell functions,” Blood, vol. 113, no. 14, pp. 3218–3225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. D. Martinez, C. Palmer, D. Simar et al., “Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders,” Liver International, vol. 35, no. 2, pp. 463–472, 2015. View at Publisher · View at Google Scholar · View at Scopus
  152. A. L. L. Rocha, P. Carrarelli, R. Novembri et al., “Activin A stimulates interleukin 8 and vascular endothelial growth factor release from cultured human endometrial stromal cells: possible implications for the pathogenesis of endometriosis,” Reproductive Sciences, vol. 19, no. 8, pp. 832–838, 2012. View at Publisher · View at Google Scholar · View at Scopus
  153. R. Linko, M. P. Hedger, V. Pettilä et al., “Serum activin A and B, and follistatin in critically ill patients with influenza A(H1N1) infection,” BMC Infectious Diseases, vol. 14, no. 1, article 253, 2014. View at Publisher · View at Google Scholar · View at Scopus
  154. W.-H. Lee, M.-H. Chung, Y.-H. Tsai, J.-L. Chang, and H.-M. Huang, “Interferon-γ suppresses activin A/NF-E2 induction of erythroid gene expression through the NF-κB/c-Jun pathway,” American Journal of Physiology—Cell Physiology, vol. 306, no. 4, pp. C407–C414, 2014. View at Publisher · View at Google Scholar · View at Scopus
  155. T. N. Q. Pham, D. M. H. Lin, P. M. Mulrooney-Cousins et al., “Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment,” Journal of Medical Virology, vol. 85, no. 3, pp. 441–448, 2013. View at Publisher · View at Google Scholar · View at Scopus
  156. J. Howell, P. Angus, P. Gow, and K. Visvanathan, “Toll-like receptors in hepatitis C infection: Implications for pathogenesis and treatment,” Journal of Gastroenterology and Hepatology, vol. 28, no. 5, pp. 766–776, 2013. View at Publisher · View at Google Scholar · View at Scopus
  157. M. Perić, Z. Bošnjak, B. Šarkanj et al., “Polymorphisms of Toll-like receptors 2 and 4 in chronically infected hepatitis C patients from north-east Croatia,” Archives of Virology, vol. 160, no. 1, pp. 297–304, 2015. View at Publisher · View at Google Scholar
  158. E. Zhang and M. Lu, “Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection,” Medical Microbiology and Immunology, vol. 204, no. 1, pp. 11–20, 2015. View at Publisher · View at Google Scholar
  159. G. Boghdadi and W. M. Seleem, “Differential expression of Toll-like receptors 7 & 8 mRNA in monocytes of patients with chronic hepatitis C infection: correlation with interferon and ribavirin treatment,” Egyptian Journal of Immunology, vol. 21, pp. 67–75, 2014. View at Google Scholar
  160. R. Broering, M. Lu, and J. F. Schlaak, “Role of toll-like receptors in liver health and disease,” Clinical Science (Lond), vol. 121, no. 10, pp. 415–426, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. S.-Y. Wang, G.-X. Tai, P.-Y. Zhang, D.-P. Mu, X.-J. Zhang, and Z.-H. Liu, “Inhibitory effect of activin A on activation of lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells,” Cytokine, vol. 42, no. 1, pp. 85–91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. N. Li, X. Cui, J. Ge et al., “Activin A inhibits activities of lipopolysaccharide-activated macrophages via TLR4, not of TLR2,” Biochemical and Biophysical Research Communications, vol. 435, no. 2, pp. 222–228, 2013. View at Publisher · View at Google Scholar · View at Scopus
  163. M.-C. Londoño, J. G. Abraldes, J. Altamirano, T. Deacens, and X. Forns, “Clinical trial watch: reports from the liver meeting (American Association for the Study of Liver Diseases), Boston, November 2014,” Journal of Hepatology, 2015. View at Publisher · View at Google Scholar
  164. D. P. Webster, P. Klenerman, and G. M. Dusheiko, “Hepatitis C,” The Lancet, 2015. View at Publisher · View at Google Scholar
  165. T. Hassanein, K. D. Sims, M. Bennett et al., “A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection,” Journal of Hepatology, 2015. View at Publisher · View at Google Scholar
  166. M. D. Sadler and S. S. Lee, “Revolution in hepatitis C antiviral therapy,” British Medical Bulletin, 2015. View at Publisher · View at Google Scholar